Anti-transplant new drugs! Novartis JAK inhibitor Jakavi treats steroid incurable chronic graft anti-host disease (GvHD) Phase 3 clinical success!

ruxolitinib is a pioneering oral Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitors.
the drug's current symptoms include bone fibrosis, true erythrocytosis (PV), corticosteroid incurable acute graft anti-host disease (GvHD).
the U.S. market, the drug is branded Jakafi and sold by Incyte, and outside the U.S., the drug is named Jakavi and is sold by Novaral.
Currently, Incyte is also developing ruxolitinib emulsions, which are being clinically developed in Phase III: (1) for the treatment of patients with mild to moderate idiopathic dermatitis (TRuE-AD) and (2) for the treatment of adolescent and adult vitiligo (TRuE-V).
Incyte has global rights to develop and commercialize ruxolitinib emulsions.
previously published Phase II study data showed that patients in the ruxolitinib emulsion treatment group had significantly improved their facial vitiligo severity index scores and significantly improved their overall vitiligo skin loss complex compared to the additive control (drug-free cream) group.
february this year, ruxolitinib emulsion treatment for special dermatitis Phase III project was a success.
() Original origin: Novartis announces first data from REACH3 trial show Jakavi? (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD。